Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Tasly Pharma Selects ICON for Global Phase III Trial of TCM Heart Drug

publication date: Nov 21, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tasly Pharmaceuticals has chosen ICON, the Dublin-based CRO, to conduct a global Phase III trial of Tasly’s oral TCM treatment for angina. The drug, known alternately as T89, Dantonic® and Cardiotonic, could be the first TCM to win FDA approval in the US. In June of this year, Tasly announced it would invest $40 million into a US facility to support Dantonic. More details....

Stock Symbols: (SHA: 600535) (NSDQ: ICLR)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners